⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL178427 | 1.00 | — | — | |
| SCHEMBL16020340 | 1.00 | — | — | |
| SCHEMBL7818386 | 0.83 | HRH3 (0.38) | — | |
| SCHEMBL9935790 | 0.82 | HRH3 (0.41) | — | |
| SCHEMBL9936731 | 0.82 | HRH3 (0.41) | — | |
| SCHEMBL13887656 | 0.80 | — | — | |
| SCHEMBL1753592 | 0.80 | — | — | |
| SCHEMBL13887646 | 0.80 | — | — | |
| SCHEMBL25111815 | 0.78 | — | — | |
| Bromide SCHEMBL18394892 | 0.78 | HRH3 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125384-A1 | INDAZOLE INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260085077-A1 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2026-03-26 | — | — | US | disclosed |
| WO-2023235384-A1 | COMPOUNDS FOR ENHANCING READ THROUGH OF GENES CONTAINING PREMATURE TERMINATION CODONS AND METHODS FOR MAKING AND USING THE SAME | SANOFI US SERVICES INC. (US) | 2023-12-07 | — | — | WO | disclosed |
| CN-114369094-B | Trifluoromethyl substituted sulfonamide selective BCL-2 inhibitors | 正大天晴药业集团股份有限公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-114369094-A | Trifluoromethyl substituted sulfonamide selective BCL-2 inhibitors | 正大天晴药业集团股份有限公司 | 2022-04-19 | — | — | CN | disclosed |
| CN-111868059-B | Trifluoromethyl substituted sulfonamide selective BCL-2 inhibitors | 正大天晴药业集团股份有限公司 | 2021-12-03 | — | — | CN | disclosed |
| US-20210300940-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-09-30 | — | — | US | disclosed |
| EP-3830080-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | Merck Patent GmbH (DE) | 2021-06-09 | — | — | EP | disclosed |
| CN-112513024-A | TLR7/8 antagonists and uses thereof | 默克专利股份公司 | 2021-03-16 | — | — | CN | disclosed |
| WO-2020238785-A1 | METHYL- AND TRIFLUOROMETHYL-CONTAINING DISUBSTITUTED SULFONAMIDE SELECTIVE BCL-2 INHIBITOR | 正大天晴药业集团股份有限公司 | 2020-12-03 | — | — | WO | disclosed |
| CN-111868059-A | Trifluoromethyl substituted sulfonamide selective BCL-2 inhibitors | 正大天晴药业集团股份有限公司 | 2020-10-30 | — | — | CN | disclosed |
| WO-2020025517-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2020-02-06 | — | — | WO | disclosed |
| WO-2019185025-A1 | TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR | 正大天晴药业集团股份有限公司 | 2019-10-03 | — | — | WO | disclosed |
| US-9808466-B2 | Macrocyclic compounds as protein kinase inhibitors | FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III | 2017-11-07 | — | — | US | disclosed |
| US-20160296528-A1 | MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) (ES) | 2016-10-13 | — | — | US | disclosed |
| US-20140256717-A1 | MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2014-09-11 | — | — | US | disclosed |
| US-20090163495-A1 | MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2009-06-25 | — | — | US | disclosed |
| US-7157457-B2 | Compounds useful in the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2007-01-02 | — | — | US | disclosed |